Mukund Paravasthu Sells 5,377 Shares of NovoCure (NASDAQ:NVCR) Stock

NovoCure Limited (NASDAQ:NVCR) COO Mukund Paravasthu sold 5,377 shares of NovoCure stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $13.31, for a total value of $71,567.87. Following the transaction, the chief operating officer directly owned 116,078 shares in the company, valued at approximately $1,544,998.18. The trade was a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Mukund Paravasthu also recently made the following trade(s):

• On Thursday, March 5th, Mukund Paravasthu sold 43,246 shares of NovoCure stock. The stock was sold at an average price of $13.77, for a total transaction of $595,497.42.

NovoCure Price Performance

NASDAQ NVCR opened at $13.04 on Friday. NovoCure Limited has a 12 month low of $9.82 and a 12 month high of $21.55. The stock has a market cap of $1.48 billion, a price-to-earnings ratio of -10.69 and a beta of 0.71. The company’s 50 day moving average is $12.74 and its two-hundred day moving average is $12.71. The company has a current ratio of 2.90, a quick ratio of 1.50 and a debt-to-equity ratio of 0.70.

NovoCure (NASDAQ:NVCR) last posted its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.19. The business had revenue of $174.35 million during the quarter, compared to analyst estimates of $174.40 million. NovoCure had a negative net margin of 20.79% and a negative return on equity of 39.11%. The company’s revenue was up 8.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.61) earnings per share. As a group, research analysts anticipate that NovoCure Limited will post -1.3 earnings per share for the current year.

Hedge Funds Weigh In On NovoCure

A number of hedge funds and other institutional investors have recently modified their holdings of NVCR. Morgan Stanley increased its holdings in NovoCure by 453.4% in the 4th quarter. Morgan Stanley now owns 5,069,895 shares of the medical equipment provider’s stock valued at $65,554,000 after acquiring an additional 4,153,741 shares during the last quarter. Soleus Capital Management L.P. lifted its stake in NovoCure by 25.0% in the 2nd quarter. Soleus Capital Management L.P. now owns 6,904,302 shares of the medical equipment provider’s stock worth $122,897,000 after purchasing an additional 1,382,888 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in shares of NovoCure by 1,093.2% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,223,755 shares of the medical equipment provider’s stock valued at $15,823,000 after purchasing an additional 1,121,192 shares during the last quarter. American Century Companies Inc. grew its position in shares of NovoCure by 1,354.7% during the second quarter. American Century Companies Inc. now owns 1,029,874 shares of the medical equipment provider’s stock valued at $18,332,000 after purchasing an additional 959,079 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of NovoCure during the fourth quarter valued at about $11,991,000. Institutional investors own 84.61% of the company’s stock.

Key NovoCure News

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Q4 results beat EPS expectations (reported ($0.22) vs. ($0.41) est.) and revenue rose ~8.2% year‑over‑year — a fundamental positive that supports a recovery narrative and gives analysts a basis for higher targets. MarketBeat NVCR coverage
• Positive Sentiment: Some sell‑side firms remain constructive (e.g., HC Wainwright raised its target and several analysts maintain Buy ratings), providing upside scenarios if clinical/commercial momentum continues. Analyst notes (MarketBeat)
• Neutral Sentiment: Brokerage consensus is an overall “Hold,” signaling limited near‑term conviction for a sustained re‑rating despite divergent analyst targets. NovoCure receives average “Hold” rating
• Neutral Sentiment: High institutional ownership (~84.6%) concentrates share control; that reduces free float but means large insider blocks can have outsized market impact when sold. Institutional holdings (MarketBeat)
• Neutral Sentiment: Minor individual insider sale by Michal Nath Puri (1,100 shares) is immaterial alone but contributes to the overall recent selling narrative. InsiderTrades alert
• Negative Sentiment: Chairman William F. Doyle sold a large block (71,887 shares, ≈$933k), trimming his stake by ~18% — a substantial single insider sale that markets typically read as negative signaling. SEC filing: Doyle sale
• Negative Sentiment: Multiple senior executives (COO Mukund Paravasthu, CEO Frank Leonard, CFO Christoph Brackmann and others) executed notable sales in the same window — an aggregated pattern that likely amplified selling pressure and contributed to intraday weakness. SEC filings: Executive sales summary

Analyst Ratings Changes

A number of brokerages have issued reports on NVCR. HC Wainwright increased their price target on NovoCure from $47.00 to $49.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Weiss Ratings restated a “sell (e+)” rating on shares of NovoCure in a research report on Thursday, January 22nd. Wedbush reaffirmed a “neutral” rating and issued a $18.00 price objective on shares of NovoCure in a research note on Thursday, January 15th. Finally, Evercore set a $20.00 target price on NovoCure in a research report on Monday, January 5th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, NovoCure currently has a consensus rating of “Hold” and a consensus price target of $26.93.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.